Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk.

abstract：:Aldosterone, a steroid hormone with mineralocorticoid activity, is far more than merely a salt-and-water hormone. Aldosterone has a number of non-classical, mineralocorticoid receptor (MR)-mediated actions, including tissue remodeling, modulation of vascular tone and stimulating inflammation and fibrosis, which may fu...

journal_title：Current vascular pharmacology

authors： Waanders F,de Vries LV,van Goor H,Hillebrands JL,Laverman GD,Bakker SJ,Navis G

更新日期：2011-09-01 00:00:00

abstract：:Post-transplant diabetes mellitus (PTDM) and dyslipidaemia are the most common metabolic complications in kidney transplant recipients (KTR). They are associated with a higher risk of lower graft function and survival, as well as an increased risk of cardiovascular disease (CVD). The aim of this review is to provide c...

journal_title：Current vascular pharmacology

authors： Anagnostis P,Paschou SA,Spartalis E,Sarno G,De Rosa P,Muscogiuri G

更新日期：2020-01-01 00:00:00

abstract：OBJECTIVE:To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment. METHODS:Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS...

journal_title：Current vascular pharmacology

authors： Wang LY,Tang JY,Liu J,Lu W,Yu YN,Chen BW,Wu HL,Su LY,Jing ZW,Hu SY,Liu XL,Yang XY,Li GX,Dong B,Wang DH,Xue J,Wang XF,Li ZM,Liu SR,Liu SS,Chen QG,Zhang L,Wang Z,Shen CT,Wang YY

更新日期：2015-01-01 00:00:00

abstract：:Obesity is a highly prevalent complex trait that raises the risk of other chronic diseases such as type 2 diabetes, certain cancers, sleep apnea, and cardiovascular disease, and shortens lifespan. Clinical intervention studies focused on weight loss and epidemiological studies of obesity indicate that genetic variatio...

journal_title：Current vascular pharmacology

authors： Franks PW,Poveda A

更新日期：2011-07-01 00:00:00

abstract：:The recently published Assessment of Survival and Cardiovascular Events (AURORA) trial showed that rosuvastatin (10 mg/d) compared with placebo did not result in a significant reduction in vascular events despite a 43% fall in low density lipoprotein cholesterol (LDL-C) levels in patients with end-stage renal disease ...

journal_title：Current vascular pharmacology

authors： Athyros VG,Tziomalos K,Karagiannis A,Mikhailidis DP

更新日期：2009-07-01 00:00:00

abstract：:During the last decades survival has significantly improved and centenarians are becoming a fast-growing group of the population. Human life span is mainly dependent on environmental and genetic factors. Favourable modifications of lifestyle factors (e.g. physical activity, diet and not smoking) and healthcare (e.g. e...

journal_title：Current vascular pharmacology

authors： Kolovou G,Barzilai N,Caruso C,Sikora E,Capri M,Tzanetakou IP,Bilianou H,Avery P,Katsiki N,Panotopoulos G,Franceschi C,Benetos A,Mikhailidis DP

更新日期：2014-01-01 00:00:00

abstract：AIM:To assess the potential differences in the metabolic and cardiovascular disease (CVD) risk between the distinct phenotypes of the Polycystic Ovary Syndrome (PCOS) according to the Rotterdam definition regardless of body mass index (BMI). PATIENTS-METHODS:The study included 300 women; 240 women with PCOS, according...

journal_title：Current vascular pharmacology

authors： Daskalopoulos G,Karkanaki A,Piouka A,Prapas N,Panidis D,Gkeleris P,Athyros VG

更新日期：2015-01-01 00:00:00

abstract：:The vascular endothelium is a monolayer of cells between the vessel lumen and the vascular smooth muscle cells. Nitric oxide (NO) is a soluble gas continuously synthesized from the amino acid L-arginine in endothelial cells by the constitutive calcium-calmodulin-dependent enzyme nitric oxide synthase (NOS). This subst...

journal_title：Current vascular pharmacology

authors： Tousoulis D,Kampoli AM,Tentolouris C,Papageorgiou N,Stefanadis C

更新日期：2012-01-01 00:00:00

abstract：:This review considers drug combinations and newer treatment strategies for patients with severe hypertriglyceridemia. Hypertriglyceridemia is associated with an atherogenic metabolic profile and in most studies with increased cardiovascular disease risk. Patients with severe hypertriglyceridemia also have increased in...

journal_title：Current vascular pharmacology

authors： Filippatos TD,Elisaf MS

更新日期：2014-01-01 00:00:00

abstract：:Statins are beneficial both in the primary and secondary prevention of atherosclerotic vascular disease and acute events in a broad spectrum of patient subgroups. However, the observed clinical benefit with statin therapy is much greater than expected through the reduction of cholesterol levels alone. Clinical and exp...

journal_title：Current vascular pharmacology

authors： Yildirir A,Müderrisoglu H

更新日期：2004-10-01 00:00:00

abstract：:High-mobility group box-1 (HMGB1) is a nuclear protein that acts as a cytokine when released into the extracellular milieu by necrotic and inflammatory cells, and is involved in inflammatory responses and tissue repair. This protein is released passively during cellular necrosis by almost all cells that have a nucleus...

journal_title：Current vascular pharmacology

authors： Biscetti F,Ghirlanda G,Flex A

更新日期：2011-11-01 00:00:00

abstract：:A considerable amount of data supports a 1.8-7.4-fold increased mortality associated with Cushing's syndrome (CS). This is attributed to a high occurrence of several cardiovascular disease (CVD) risk factors in CS [e.g. adiposity, arterial hypertension (AHT), dyslipidaemia and type 2 diabetes mellitus (T2DM)]. Therefo...

journal_title：Current vascular pharmacology

authors： Koracevic G,Stojkovic M,Lovic D,Pavlovic M,Kostic T,Kutlesic M,Micic S,Koracevic M,Djordjevic M

更新日期：2020-01-01 00:00:00

abstract：:This review provides evidence that antenatal hypoxia, which represents a significant and worldwide problem, causes prenatal programming of the lung. A general overview of lung development is provided along with some background regarding transcriptional and signaling systems of the lung. The review illustrates that ant...

journal_title：Current vascular pharmacology

authors： Papamatheakis DG,Blood AB,Kim JH,Wilson SM

更新日期：2013-09-01 00:00:00

abstract：:Cell-based therapies are a novel approach for regeneration of microvasculature. We have shown that administration of CD34-positive cells, the rich cell fraction of endothelial progenitor cells, after stroke induces angiogenesis that results in enhanced endogenous neurogenesis and functional recovery in a murine model....

journal_title：Current vascular pharmacology

authors： Uemura M,Kasahara Y,Nagatsuka K,Taguchi A

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:In the era of dual antiplatelet therapy of aspirin and clopidogrel and systematic stent implantation, Glycoprotein IIb/IIIa Inhibitors (GPI), including abciximab, eptifibatide and tirofiban, proved beneficial in improving early outcome of Percutaneous Coronary Intervention (PCI), especially in higher risk cl...

journal_title：Current vascular pharmacology

authors： Rubboli A,Patti G

更新日期：2018-01-01 00:00:00

abstract：:The pathogenesis of obesity, insulin resistance and hypertension begins with an interaction between genetic factors and environmental factors. The search for the underlying genetic basis of these conditions has yielded disappointing results. It is possible that the importance of environmental influences has been under...

journal_title：Current vascular pharmacology

authors： Sharma V,McNeill JH

更新日期：2006-10-01 00:00:00

abstract：:Urocortin comprises a group of endogenously produced peptide hormones that belong to the corticotropinreleasing factor (CRF) family with promising future as potential drugs for the treatment of heart disease. Members of the urocortin family are known to act as potent regulators of cardiac and vascular functions, throu...

journal_title：Current vascular pharmacology

authors： Díaz I,Smani T

更新日期：2013-07-01 00:00:00

abstract：:Revascularization procedures used for the treatment of cardiovascular disease can be associated with restenosis, although drug-coated stents have greatly reduced this complication. Both type 2 diabetes (T2DM) and metabolic syndrome (MetS) are associated with a high risk for atherosclerosis and restenosis. Insulin resi...

journal_title：Current vascular pharmacology

authors： Breen DM,Giacca A

更新日期：2011-05-01 00:00:00

abstract：BACKGROUND:Dyslipidaemia is a risk factor for macrovascular complications in patients with type 2 diabetes mellitus (T2DM). Our aim was to assess the use of lipid lowering drugs (LLDs) in patients with T2DM and co-existing dyslipidaemia. METHOD:A multicentre, non-interventional survey conducted in 6 Middle Eastern cou...

journal_title：Current vascular pharmacology

authors： Shehab A,Al-Rasadi K,Arafah M,Al-Hinai AT,Al Mahmeed W,Bhagavathula AS,Al Tamimi O,Al Herz S,Al Anazi F,Al Nemer K,Metwally O,Alkhadra A,Fakhry M,Elghetany H,Medani AR,Yusufali AH,Al Jassim O,Al Hallaq O,Baslaib FOAS

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Single-pill fixed dose combination (FDC) therapies are widely used in the treatment of arterial hypertension. OBJECTIVE:This pilot study aimed to evaluate the effects of a FDC therapy combined with therapeutic drug monitoring (TDM) on blood pressure (BP) in patients with treatment resistant hypertension. M...

journal_title：Current vascular pharmacology

authors： Kreutz R,Scholze J,Douros A

更新日期：2018-01-26 00:00:00

abstract：:Chronic kidney disease (CKD), and particularly kidney failure, is associated with accelerated atherosclerosis and approximately a 20-fold increased risk of cardiovascular death. The majority of these patients die from complications directly attributed to atherosclerosis and their life expectancy is decreased. Establis...

journal_title：Current vascular pharmacology

authors： Efstratiadis G,Tziomalos K,Mikhailidis DP,Athyros VG,Hatzitolios A

更新日期：2008-04-01 00:00:00

abstract：:Chronic venous disease (CVeD) is a debilitating condition that affects millions of individuals worldwide. The condition can result in varicose veins, or advance to severe skin changes and venous ulceration. The fundamental basis for CVeD is inflammation within the venous circulation and that it is subjected to increas...

journal_title：Current vascular pharmacology

authors： Mannello F,Ligi D,Canale M,Raffetto JD

更新日期：2014-01-01 00:00:00

abstract：:Epidemiological evidence supports a reduced prevalence of Thoracic Aortic Aneurysm (TAA) and Abdominal Aortic Aneurysm (AAA) in patients with Diabetes (DM). The mechanisms underlying this negative association are unknown. Some studies support that hyperglycemia has effects on the Extracellular Matrix (ECM), resulting ...

journal_title：Current vascular pharmacology

authors： Krizhanovskii C,Franco-Cereceda A

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Volatile Anaesthetics (VA) are commonly used worldwide for induction and/or maintenance of general anaesthesia. They act in the central nervous system to reduce sensation and motor response during surgical and invasive diagnostic procedures. VAs also have some non-anaesthetic properties in the brain when adm...

journal_title：Current vascular pharmacology

authors： Krzych LJ,Szczepanska AJ

更新日期：2018-01-01 00:00:00

abstract：:Paraoxonase-1 (PON-1) is a calcium-dependent enzyme that is synthesized in the liver and then secreted in blood where it is bound to high density lipoprotein (HDL). PON-1 is a hydrolase with a wide range of substrates, including lipid peroxides. It is considered responsible for many of the antiatherogenic properties o...

journal_title：Current vascular pharmacology

authors： Lioudaki S,Verikokos C,Kouraklis G,Ioannou C,Chatziioannou E,Perrea D,Klonaris C

更新日期：2019-01-01 00:00:00

abstract：:A number of epidemiological studies have shown that diets rich in plant-derived phenolic compounds reduce the risk of coronary heart disease. The chronic antioxidant and hypolipidemic activities of these compounds have important roles in prevention of lipoprotein oxidation and atherosclerotic lesion development. In re...

journal_title：Current vascular pharmacology

authors： Jiang F,Dusting GJ

更新日期：2003-06-01 00:00:00

abstract：:Central arterial systolic blood pressure is a very important factor in the pathophysiology of cardiovascular diseases. Central arterial pressure is a better predictor of cardiovascular risk than peripheral brachial blood pressure. Measurement of central blood pressure is useful for a diagnosis of spurious systolic hyp...

journal_title：Current vascular pharmacology

authors： Stepień M,Banach M,Jankowski P,Rysz J

更新日期：2010-11-01 00:00:00

abstract：:In end-stage renal disease patients, the leading causes of mortality are of cardiovascular (CV) origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. A contributing role of oxidative stress is postulated, which is increased even at early stages ...

journal_title：Current vascular pharmacology

authors： Roumeliotis S,Roumeliotis A,Gorny X,Mertens PR

更新日期：2021-01-01 00:00:00

abstract：:Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosi...

journal_title：Current vascular pharmacology

authors： Franczyk-Skóra B,Gluba A,Banach M,Rozentryt P,Poloński L,Rysz J

更新日期：2013-09-01 00:00:00

abstract：:Nowadays long-term outcome of heart transplantation is limited by a peculiar type of coronary atherosclerosis, known as cardiac allograft vasculopathy (CAV). Although the exact pathogenesis of CAV remains unclear, emerging evidence indicates that the endothelium plays a significant role in the onset and progression of...

journal_title：Current vascular pharmacology

authors： Osto E,Tona F,De Bon E,Iliceto S,Cella G

更新日期：2010-03-01 00:00:00